GB Sciences, Inc. has started an expansion strategy through the formation of GBS Global Biopharma Inc. "GBS Global will expedite the development of clinical programs and IP currently indicated for 60 disease and health conditions", the company explains.
The company points out that "GBS Global proprietary discovery platform generates “complex mixture” cannabinoid/terpenoid active ingredients (APIs) for specific disease and health conditions. GBS Global researchers are working with scientists in the United States, Spain, and Greece on nutraceuticals, delivery technology, and prescription drug programs."
“Canada’s policies will allow GBS Global to bring our cannabinoid medications to market quickly, safely and legally. Canada’s regulations, in particular, mean treatments can be evaluated and approved in less time than it would take in the U.S.,” says GBS Global Board Chair and CEO of GB Sciences, Inc. John Poss.
"GBS Global intellectual property portfolio of natural and synthetic cannabinoid-based complex mixtures are indicated for Parkinson’s (PD), neuropathic pain, and cardiac hypertrophy Rx programs in late pre-clinical stage of development. OTC programs for irritable bowel syndrome, sleep disorders, and psoriasis are at formulation stage in step with ongoing discussions with strategic partners in the field", the company concludes.